Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India

Back Stocks profile

Stock analysis tool for investors

Akums Drugs & Pharmaceuticals Ltd.

NSE: AKUMS | BSE:544222

₹896.95 42.70 (5.00%) 1D

Pharmaceuticals & Biotechnology

Buy Sell
Open free demat account View detailed Technical chart

Open an Account with Bigul in 5 minutes

Performance Online share trading app

Today’s low

833.40

Today’s High

897.00

52W low

725.00

52W High

1175.90

Open Price

848.90

Prev. Close

854.2500

Volume

378007.00

Value

339053378.65

Fundamentals Open free demat account

Market Cap

14117.50

Price to Earnings

0.00

Price to Book Value

19.60

Dividend Yield

0.00

PE to Growth

0.00

Op Revenue TTM

0.00

Net Profit TTM

0.00

Cash From Operating Activity

498.26

Return on Equity %

-0.56

EMA & SMA

Online share trading app Open free demat account

Bullish Moving Averages

5

Bearish Moving Averages

2

5Day EMA

874.2

10Day EMA

882.9

12Day EMA

885.4

20Day EMA

908.5

EMA

EMA

EMA

EMA

5Day SMA

863

10Day SMA

884.8

20Day SMA

914.8

SMA

SMA

SMA

SMA

SMA

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

03 Sep, 2024

45.2

Week

42.1

Month

46.9

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

875.75

PIVOT

First Resistance

918.15

Second Resistance

939.35

Third Resistance

981.75

First Support

854.55

Second Support

812.15

Third Support

790.95

Relative Strength Index

57.8

Money Flow Index

31.54

MACD

MACD Signal

Average True Range

58.23

Average Directional Index

Rate of Change (21)

Rate of Change (125)

Commodity Channel Index

-35.7

Williams %R

-78.6

BETA

1 Month

3 Month

1 Year

3 Year

PRICE CHANGE ANALYSIS

↑ 4.84%

1 Week

Low

High

821

898.3

↑ 32.1%

1 Month

Low

High

725

1175.9

↑ 32.1%

3 Months

Low

High

725

1175.9

↑ 32.1%

6 Months

Low

High

725

1175.9

↑ 32.1%

1 Year

Low

High

725

1175.9

Indicator Jun 2024 Mar 2024 Jun 2023 Graph
Total Qtr Revenue cr 343.45 325.02 336.01
Operating Expenses Qtr 273.59 358.89 502.76
Operating Profit Qtr 43.68 -60.53 -187.15
EBIDT Qtr Cr 69.86 -35.16 -166.75
Depreciation Qtr 9.38 9.09 7.40
Net Profit Qtr 41.88 -57.87 -189.67
Basic EPS Qtr 2.93 -4.04 -13.26
Indicator Mar 2023 Graph
Total Revenue Annual 1382.98
Operating Expenses Annual Cr 1044.95
Operating Profit Annual 241.88
Operating Profit Margin Annual % 17.49
Total Expenses Annual Cr 1088.13
EBIDT Annual Cr 338.03
EBIDT Annual margin % 24.44
Depreciation 30.00
PAT Before ExtraOrdinary Items Annual Cr 125.43
Net Profit Annual 125.43
Basic EPS Annual 8.77
Indicator Mar 2023 Graph
Total ShareHolders Funds Annual 311.50
Minority Interest Liability Annual Cr -
Total Non Current Liabilities Annual Cr 1086.15
Total Current Liabilities Annual Cr 496.56
Total Capital Plus Liabilities Annual Cr 1894.21
Fixed Assets Annual 288.65
Total Non Current Assets Annual 1373.12
Total Current Assets Annual 521.08
Total Assets Annual 1894.21
Contingent Liabilities plus Commitments Annual Cr 0.00
Indicator Mar 2023 Graph
Cash from Operating Activity Annual 94.01
Cash from Investing Activity Annual -202.17
Cash from Financing Annual Activity 89.90
Net Cash Flow Annual -18.25
Indicator Mar 2023 Graph
Book Value Per Share Annual 21.77
ROE Annual % 40.26
ROCE Annual % 22.03
Total Debt to Total Equity Annual 0.47
EBDIT Annual Margin % 26.26
Indicator Jun 2024 Mar 2024 Jun 2023 Graph
Total Qtr Revenue cr 1025.66 954.45 977.98
Operating Expenses Qtr 891.10 941.22 1095.15
Operating Profit Qtr 128.02 2.99 -125.27
EBIDT Qtr Cr 134.56 13.45 -116.93
Depreciation Qtr 34.06 33.95 29.72
Net Profit Qtr 60.17 -41.32 -188.23
Basic EPS Qtr 4.21 -2.89 -13.16
Indicator Mar 2023 Graph
Total Revenue Annual 3700.93
Operating Expenses Annual Cr 3316.87
Operating Profit Annual 337.95
Operating Profit Margin Annual % 9.13
Total Expenses Annual Cr 3475.93
EBIDT Annual Cr 384.06
EBIDT Annual margin % 10.38
Depreciation 112.81
PAT Before ExtraOrdinary Items Annual Cr 98.02
Net Profit Annual 94.86
Basic EPS Annual 6.63
Indicator Mar 2023 Graph
Total ShareHolders Funds Annual 717.19
Minority Interest Liability Annual Cr 6.18
Total Non Current Liabilities Annual Cr 1277.59
Total Current Liabilities Annual Cr 1265.57
Total Capital Plus Liabilities Annual Cr 3266.53
Fixed Assets Annual 1198.40
Total Non Current Assets Annual 1342.37
Total Current Assets Annual 1924.16
Total Assets Annual 3266.53
Contingent Liabilities plus Commitments Annual Cr 153.65
Indicator Mar 2023 Graph
Cash from Operating Activity Annual 176.63
Cash from Investing Activity Annual -304.70
Cash from Financing Annual Activity 124.54
Net Cash Flow Annual -3.53
Indicator Mar 2023 Graph
Book Value Per Share Annual 50.56
ROE Annual % 13.22
ROCE Annual % 13.55
Total Debt to Total Equity Annual 0.75
EBDIT Annual Margin % 10.50
Name Holding Percent Holding Id Pledged % Locked %
Name Holding Percent Holding Id Pledged % Locked %
Sandeep Jain 17.24 92929676 0 100
Sanjeev Jain 17.23 92929677 0 100
Akums Master Trust 40.79 92929694 0 100
Name Holding Percent Holding Id
Name Holding Percent Holding Id
Ruby Qc Investment Holdings Pte Ltd 4.62 92929724
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Ex-Date Split Ratio Record Date
Ex-Date Purpose Notes
Aug 24, 2024 Quarterly Results -
Ex-Date Bonus Ratio Record Date
Bigul
04 Sep 2024

Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Transcript of Earnings / Analyst Conference Call held for limited reviewed un-audited financial results of Q1 FY25.
Bigul
30 Aug 2024

Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Audio recording of Earnings/Analysts Conference Call held for limited reviewed un-audited financial results of Q1 FY25.
28 Aug 2024

Akums Drugs: Double-Digit Growth In Branded & Generic Exports | NDTV Profit
Bigul
27 Aug 2024

Akums Drugs and Pharmaceuticals back in black with 42 crore standalone net profit for June quarter

 The company reported a revenue of 317 crore for the period under review. Revenues were near flat on a y-o-y basis at 316 crore
Bigul
26 Aug 2024

Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Newspaper Publication
Bigul
24 Aug 2024

Akums Drugs and Pharmaceuticals Ltd - 544222 - Appointment Of Mr. Amrut Medhekar As Chief Executive Officer- CDMO Business

 Appointment of Mr. Amrut Medhekar as Chief Executive Officer- CDMO Business
Bigul
24 Aug 2024

Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Investor Presentation
Bigul
24 Aug 2024

Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release
Bigul
24 Aug 2024

Akums Drugs and Pharmaceuticals Ltd - 544222 - Un-Audited Financial Results For The Quarter Ended 30.06.2024

 Un-Audited Financial Results for the quarter ended 30.06.2024
Bigul
24 Aug 2024

Akums Drugs and Pharmaceuticals Ltd - 544222 - Board Meeting Outcome for Outcome Of Board Meeting

 Outcome of Board Meeting
See all News

FAQs

Investment Platform in India

The latest market price of Akums Drugs & Pharmaceuticals Ltd. on NSE was Rs. 896.95 as of today.

The opening share price of Akums Drugs & Pharmaceuticals Ltd. was Rs. 848.90 as of today.

The 52-week high share price of Akums Drugs & Pharmaceuticals Ltd. was Rs. 1175.90.

The 52 week low share price of Akums Drugs & Pharmaceuticals Ltd. was Rs. 725.00.

Please find Corporate actions section for more details.

The PE ratio of Akums Drugs & Pharmaceuticals Ltd. is 0.00. Please refer to the Fundamentals section for further details.

Please find Corporate actions section for more details.

Please find Corporate actions section for more details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please find Corporate actions section for more details.

Please find Corporate actions section for more details.

Please find Corporate actions section for more details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Akums Drugs & Pharmaceuticals Ltd..

Investment Platform in India
Close

Let's Open Free Demat Account